

OBJECTIVES:

1. Learn about RSV hospital and ICU admission rates and characteristics of children admitted in the 2021-2023 RSV seasons.
2. Recognize the burden of RSV disease in infants, young children and pregnant women and people.
3. Appreciate self-reported attitudes and preferences between RSVpreF vaccination and nirsevimab for infants.
4. Appreciate the global burden of severe RSV illness in low-middle income countries.
5. Learn about the priorities for global RSV prevention as dictated by the World Health Organization.
6. Appreciate which children should receive nirsevimab after maternal RSVpreF vaccination and for a second RSV season.
7. Appreciate the real-world evidence of the effectiveness of nirsevimab across studies.
8. Learn that RSVpreF alone is safe and effective for RSV prevention in newborns and infants in the real world.
9. Appreciate that long-acting, new monoclonal antibodies are paving the way for RSV prevention in infants.
10. Learn what is in the RSV vaccine pipeline for infants and potential adverse events.
11. Appreciate the changes for the 2025-2026 RSV season as dictated by the Ontario Ministry and the Medical officer of Health.

This event has been approved by the Canadian Paediatric Society for a maximum of 6 credit hours as an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada.

The specific opinions and content of this event are not necessarily those of the CPS and are the responsibility of the organizer(s) alone.

FURTHER INFORMATION

Please Contact

Dr. Bosco Paes
paes@mcmaster.ca

Louise Bruns
Program Coordinator
louise@brunsconsulting.ca



McMaster Children's Hospital
Presents

RSV COORDINATORS CONFERENCE

INTERACTIVE LIVE
VIRTUAL CONFERENCE

Friday
October 3, 2025

PROGRAMME COMMITTEE

Dr. Bosco Paes
Dr. Jeffrey Pernica
Dr. Sandra Seigel

SPEAKERS

Tiffany Fitzpatrick, PhD, MPH
Public Health Ontario, Centre for Vaccine Preventable
Diseases, University of Toronto

Nathalie Mazur, MD, PhD
Wilhelmina Children's Hospital
University Medical Center Utrecht
Utrecht, Netherlands

April Killikelly, PhD
Centre for Immunization Programs
Public Health Agency of Canada

Erin Sparrow, MD, BSc, MSc, PhD
Department of Immunization, Vaccines and
Biologicals, WHO, Geneva, Switzerland

Simon Drysdale, MBBS, PhD, FRCPC, FHEA
Oxford Vaccine Group, Paediatric Infectious
Diseases and Immunology, Children's Hospital
Oxford, United Kingdom

Joanne Langley MD, MSc
Division Head, Pediatric Infectious
Diseases and Department of Community Health and
Epidemiology, Dalhousie University, Halifax

Michelle Morais, MD, FRCS(C), DRCPSC
Division of Maternal-Fetal Medicine,
Faculty of Health Sciences, McMaster University

Pascal Lavoie, MDCM, PhD, FRCPC
Division of Neonatology, Clinician-Scientist
University of British Columbia

Jesse Papenburg, MD, MSc, FRCPC
Division of Pediatric Infectious
Diseases, McGill University

Barry Rodgers-Gray, MSc, PhD
Managing Director, Violicom Medical Limited
England, United Kingdom

Daniel Warshafsky, MD, MPH, CCFP (SEM), Dip
Sport Med, FRCPC
Associate Chief Medical Officer of Health
Office of the Chief Medical Officer of Health
Public Health

- 7:30-8:15 **REGISTRATION**
- 8:15-8:30 **INTRODUCTION** – Dr. B. Paes
- 8:30-9:00 Pediatric RSV hospitalizations 2017-2023
Dr. T. Fitzpatrick
- 9:00-9:30 RSV in Low-Middle-Income countries
Dr. N. Mazur
- 9:30-10:00 Burden of RSV disease in infants, children and
pregnant women and people
Dr. A. Killikelly
- 10:00-10:15 **BREAK**
- 10:15-10:45 WHO global recommendations for the use of
maternal RSVpreF and nirsevimab
Dr. E. Sparrow
- 10:45-11:15 Real world effectiveness of RSVpreF alone for the
prevention of RSV in infants
Dr. S. Drysdale
- 11:15-11:45 Real-world effectiveness of nirsevimab against
RSV disease in infants
Dr. J. Langley
- 11:45-12:15 Acceptance and preference of RSVpreF vaccine
and nirsevimab among pregnant and postpartum
persons in Canada
Dr. M. Morais
- 12:15-12:45 **BREAK**
- 12:45-13:15 Children with complex disorders at risk
for RSV hospitalization in the first two seasons.
Dr. P. Lavoie
- 13:15-13:45 RSV vaccine pipeline for infants: Are we there
yet? Dr. J. Papenburg
- 13:45-14:15 Long-acting monoclonal antibodies for RSV
prevention
Dr. B. Rodgers-Gray
- 14:15-15:00 The Provincial MOH for the Infant RSV Program
for the 2025-2026 season and the logistics for the
application, receipt and distribution of
prophylaxis
Dr. D. Warshafsky
- 15:00-15:15 **EVALUATIONS AND CONCLUSION**

RSV VIRTUAL COORDINATORS CONFERENCE

Interactive Live Virtual Program

Friday
October 3, 2025

NO REGISTRATION FEES!
Join us for the interactive live
virtual conference!

Only preregistered attendees will be
admitted.

Register online at:
www.mcmaster-pediatrics.ca